Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

(15,032,405) -

-------------------------------------------------------------------------

Deficit, end of period (32,533,633) (21,476,594) (32,533,633)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Loss per share -

basic and diluted (0.25) (0.18)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average common shares

outstanding 44,750,964 35,751,822

-------------------------------------------------------------------------

-------------------------------------------------------------------------

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOWS

-------------------------------------------------------------------------

Period from

incorporation

on August 11,

1999 to

Years ended November 30, November 30,

2007 2006 2007

$ $ $

-------------------------------------------------------------------------

Cash provided by (used in):

Operating activities:

Loss for the period (11,057,039) (6,444,189) (32,533,633)

Items not involving cash:

Amortization of:

Facilities and equipment 389,713 215,793 1,278,871

Deferr
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 ... ) has announced the addition of the ... (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, ... Flow Cytometry), End Users - Global Forecast ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/1/2015)... N.J. , June 1, 2015  Janssen ... the Phase 3 multicenter study SAR3007, which demonstrated ... trabectedin (YONDELIS ® ) compared to dacarbazine in ... previously treated with an anthracycline and at least ... randomized Phase 3 study ever conducted in this ...
(Date:6/1/2015)... 1, 2015 About Bio-alcohols ... sugar or cellulose. Bio-alcohols are primarily used in the ... a replacement for gasoline in cars. Technavio,s analysts forecast ... of 9 percent over the period 2014-2019. ... can be segmented into five: transportation, infrastructure, medical, and ...
(Date:6/1/2015)... 1, 2015  Novartis is highlighting data from ... an investigational chimeric antigen receptor (CAR) T cell ... of specific types of hard-to-treat non-Hodgkin lymphoma. Findings ... of Pennsylvania,s Perelman School of Medicine (Penn) in ... B-cell lymphoma (DLBCL) and follicular lymphoma (FL) found ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... Standards and Technology (NIST) colored lots of eggs recently. ... smallin fact, too small to see without a microscope. ... strategies for making future low-power computer memories. For ... used electron-beam lithography to make thousands of nickel-iron magnets, ...
... new kind of cloaking material that can render ... this design can,t translate into an invisibility cloak ... in diagnostics, security, and communication. The cloak, ... engineering at Northwestern,s McCormick School of Engineering and ...
... 27, 2011 Talecris Biotherapeutics Holdings Corp. ("Talecris") (NASDAQ: ... for the three months ended March 31, 2011 and ... Exchange Commission (SEC). First quarter 2011 net ... million from $381.0 million in the first quarter of ...
Cached Biology Technology:Good eggs: NIST nanomagnets offer food for thought about computer memories 2Researchers create terahertz invisibility cloak 2Talecris Biotherapeutics Announces First Quarter 2011 Results 2Talecris Biotherapeutics Announces First Quarter 2011 Results 3Talecris Biotherapeutics Announces First Quarter 2011 Results 4Talecris Biotherapeutics Announces First Quarter 2011 Results 5Talecris Biotherapeutics Announces First Quarter 2011 Results 6Talecris Biotherapeutics Announces First Quarter 2011 Results 7Talecris Biotherapeutics Announces First Quarter 2011 Results 8Talecris Biotherapeutics Announces First Quarter 2011 Results 9Talecris Biotherapeutics Announces First Quarter 2011 Results 10Talecris Biotherapeutics Announces First Quarter 2011 Results 11Talecris Biotherapeutics Announces First Quarter 2011 Results 12Talecris Biotherapeutics Announces First Quarter 2011 Results 13Talecris Biotherapeutics Announces First Quarter 2011 Results 14Talecris Biotherapeutics Announces First Quarter 2011 Results 15Talecris Biotherapeutics Announces First Quarter 2011 Results 16
(Date:6/1/2015)... , June 1, 2015 ... & Touchless Sensing Market by Technology (Touch-based & Touchless), ... Sanitary Equipment), & by Geography - Global Forecast to ... Sensing Market is expected to reach $23.55 Billion by ... 2020. Browse 83 market data T ...
(Date:6/1/2015)... , June 1, 2015 ... "Next Generation Biometrics Market by Application (Government, Military ... Travel & Immigration, and Security), Technology (Face Recognition, ... Signature Recognition, Vein Recognition, and Others), Function (Contact ... , Europe , APAC, ...
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... is available in Spanish . , U.S. Department ... to improve soil on degraded land so it can be ... USDA,s Agricultural Research Service (ARS) at the agency,s Appalachian Farming ... or replacement subsoils and topsoils to build better and less-costly ...
... (BRONX, NY) Albert Einstein College of Medicine of ... prestigious Medal of Honor in Basic Science from the ... into the critical role the tumor microenvironment plays in ... the innate immune cells called macrophages play both in ...
... diarrheal disease claims the lives of 1.3 million children ... majority of these deaths occur in developing countries of ... greatly reduce deaths and save lives. To bring attention ... Vietnam Ministry of Health, the National Pediatric Hospital of ...
Cached Biology News:Improving soil for better lawns and gardens 2Einstein researcher receives American Cancer Society Medal of Honor 2Symposium in Vietnam to discuss integrated approach to defeating diarrheal disease 2Symposium in Vietnam to discuss integrated approach to defeating diarrheal disease 3
Recombinant Viral CCI/Fc Chimera, CF...
... Guinea Pig Serum • Guinea Pig serum ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: